Author: Tom Wilemon
Funding renewed for Meharry, TSU, Vanderbilt-Ingram partnership on cancer disparities
Sep. 24, 2021—The Meharry Medical College/Vanderbilt-Ingram Cancer Center/Tennessee State University Partnership has received renewed funding from the NCI to continue long-standing collaborations to eliminate cancer health disparities.
Eng named co-chair of NCI clinical trials steering committee
Sep. 23, 2021—Vanderbilt's Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.
Winkfield named to National Cancer Advisory Board
Sep. 16, 2021—President Joe Biden has appointed Karen Winkfield, MD, PhD, to the National Cancer Advisory Board, where she will serve a six-year term and help guide federal initiatives that focus on cancer.
Novel immunotherapy shows robust response for multiple myeloma
Sep. 10, 2021—Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma.
Park named to new role as deputy director of Vanderbilt-Ingram Cancer Center
Aug. 19, 2021—Ben Ho Park, MD, PhD, Cornelius Abernathy Professor of Medicine, has been named deputy director of Vanderbilt-Ingram Cancer Center (VICC).
Study identifies biomarker for breast cancer response to immunotherapy
Aug. 12, 2021—A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Clinical trial to test immunotherapy for rectal cancer
Aug. 5, 2021—A new clinical trial seeks to determine whether immunotherapy in combination with short-course radiation followed by surgical resection could be a curative treatment for locally advanced rectal cancer.
Ciombor chosen for NCI clinical investigator team leadership award
Jul. 15, 2021—Kristen Ciombor, MD, MSCI, is one of 10 physicians nationwide selected by the National Cancer Institute (NCI) for the 2021 Cancer Clinical Investigator Team Leadership Award.
Susan G. Komen funds VICC breast cancer initiatives
Jul. 15, 2021—Susan G. Komen has announced breast cancer research grants totaling $14 million, including funding for three separate initiatives led by Vanderbilt-Ingram Cancer Center (VICC) researchers.
Davis promoted to Vice President for VUMC Cancer Care Network and Strategy
Jul. 14, 2021—Nancy Davis, MD, has been promoted to Vice President for Cancer Care Network and Strategy at Vanderbilt University Medical Center, a new position responsible for developing provider relationships with other health care systems and expanding access to oncology care throughout Tennessee and other states.
Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma
Jul. 1, 2021—A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.
Tuya Pal named Komen Scholar
Jun. 24, 2021—Susan G. Komen announced on June 23 that Tuya Pal, MD, associate director for Cancer Health Disparities at Vanderbilt-Ingram Cancer Center (VICC) and Ingram Professor of Cancer Research, has been named a Komen Scholar.
